About Cytokinetics

Cytokinetics discovers, develops, and commercialises medicines that directly impact muscle mechanics. As a leader in muscle biology for over 25 years, the company creates small molecule muscle activators and inhibitors to treat debilitating diseases characterised by compromised muscle function, including heart failure, hypertrophic cardiomyopathy, and neuromuscular conditions. It received its first FDA approval in 2025. Every medicine Cytokinetics develops aims to preserve and extend independence for people with cardiovascular and neuromuscular muscle dysfunction. The company builds specialty treatment options through rigorous clinical development, having completed pivotal Phase 3 trials. Patients are the driving force behind the science.